Calcium dobesilate in the treatment of diabetic retinopathy

Treatments in Endocrinology

Volumn 4, Issue 4, 2005, Pages 221-232

  Garay, Ricardo P ^a,c   Hannaert, Patrick ^a   Chiavaroli, Carlo ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Vifor (International) Inc   (Switzerland)

^c NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALAGEBRIUM; ALDOSE REDUCTASE INHIBITOR; ALPHA TOCOPHEROL; AMINOGUANIDINE; ANTIDIABETIC AGENT; ANTIOXIDANT; ASCORBIC ACID; CANDESARTAN HEXETIL; DANAPAROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DOBESILATE CALCIUM; FIBRINOGEN; GLYCOSAMINOGLYCAN; INSULIN; LISINOPRIL; METFORMIN; NICANARTINE; OCTREOTIDE; PONALRESTAT; PROTEIN KINASE C INHIBITOR; PYCNOGENOL; RUBOXISTAURIN; RUTOSIDE; SOMATOSTATIN DERIVATIVE; SORBINIL; SULFONYLUREA DERIVATIVE; TOLRESTAT; TROLOX C; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ANEURYSM; ANGIOGENESIS; ANTIOXIDANT ACTIVITY; APOPTOSIS; BLINDNESS; BLOOD RETINA BARRIER; BLOOD VISCOSITY; CELL PROLIFERATION; CHRONIC VEIN INSUFFICIENCY; CLINICAL TRIAL; DEVELOPED COUNTRY; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIUM INJURY; EVIDENCE BASED MEDICINE; EYE INJURY; GASTROINTESTINAL DISEASE; GLYCATION; HEMORRHOID; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; LEUKOCYTE MIGRATION; LOW LEVEL LASER THERAPY; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RETINA MACULA EDEMA; REVIEW; SKIN MANIFESTATION; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION; TREATMENT FAILURE; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY; VITREOUS HEMORRHAGE;

ANIMALS; ANTIOXIDANTS; BLOOD-RETINAL BARRIER; CALCIUM DOBESILATE; DIABETIC RETINOPATHY; EVIDENCE-BASED MEDICINE; HUMANS; OXIDATIVE STRESS; RATS;

EID: 23744448194     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200504040-00003     Document Type: Review

References (115)

1. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003; 136: 122-35
2. Watkins PJ. Retinopathy. BMJ 2003; 326: 924-6
3. Dailey G. New strategies for basal insulin treatment in type 2 diabetes mellitus. Clin Ther 2004; 26: 889-901
4. Frank RN. Diabetic retinopathy. N Engl J Med 2004; 350: 48-58
5. Giusti C. Is medical treatment for diabetic retinopathy still an unreal dream? Med Hypotheses 2002; 59: 706-9
6. Frank RN. Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol 2002; 133: 693-8
7. Porta M, Allione A. Current approaches and perspectives in the medical treatment of diabetic retinopathy. Pharmacol Ther 2004; 103: 167-77
8. DCCT. The effect of intensive treatment of diabetes on the development and progression of complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-86
9. UKPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-13
10. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998; 105: 1801-15
11. Klein R. Prevention of visual loss from diabetic retinopathy. Surv Ophthalmol 2002; 47 Suppl. 2: S246-52
12. Arun CS, Ngugi N, Lovelock L, et al. Effectiveness of screening in preventing blindness due to diabetic retinopathy. Diabet Med 2003; 20: 186-90
13. Davis S, Alonso MD. Hypoglycemia as a barrier to glycemic control. J Diabetes Complications 2004; 18: 60-8
14. Hansson-Lundblad C, Holm K, Agardh CD, et al. A small number of older type 2 diabetic patients end up visually impaired despite regular photographic screening and laser treatment for diabetic retinopathy. Acta Ophthalmol Scand 2002; 80: 310-5
15. Bailey CC, Sparrow JM, Grey RH, et al. The national diabetic retinopathy laser treatment audit: III. Clinical outcomes. Eye 1999; 13 (Pt 2): 151-9
16. Lovestam-Adrian M, Agardh E. Photocoagulation of diabetic macular oedema: complications and visual outcome. Acta Ophthalmol Scand 2000; 78: 667-71
17. Spranger J, Pfeiffer AF. New concepts in pathogenesis and treatment of diabetic retinopathy. Exp Clin Endocrinol Diabetes 2001; 109 Suppl. 2: S438-50
18. Speicher MA, Danis RP, Criswell M, et al. Pharmacologic therapy for diabetic retinopathy. Expert Opin Emerg Drugs 2003; 8: 239-50
19. Lorenzi M, Gerhardinger C. Early cellular and molecular changes induced by diabetes in the retina. Diabetologia 2001; 44: 791-804
20. Gargiulo P, Giusti C, Pietrobono D, et al. Diabetes mellitus and retinopathy. Dig Liver Dis 2004; 36: S101-5
21. Antonetti DA, Lieth E, Barber AJ, et al. Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin Ophthalmol 1999; 14: 240-8
22. Tejerina T, Ruiz E. Calcium dobesilate: pharmacology and future approaches. Gen Pharmacol 1998; 31: 357-60
23. Berthet P, Farine JC, Barras JP. Calcium dobesilate: pharmacological profile related to its use in diabetic retinopathy. Int J Clin Pract 1999; 53: 631-6
24. Leite EB, Mota MC, de Abreu JR, et al. Effect of calcium dobesilate on the blood-retinal barrier in early diabetic retinopathy. Int Ophthalmol 1990; 14: 81-8
25. Grignolo FM, Musso M, Borromeo P, et al. Fluorescence iris angiography in the assessment of calcium dobesilate therapy in the treatment of diabetic microangiopathy. Ophthalmologica 1979; 178: 250-8
26. Nemeth B, Hudomel J, Farkas A. Effect of calcium bodesilate (Doxium®) on circulatory disorders of the retina with special emphasis on diabetic retinopathy. Ophthalmologica 1975; 170: 434-45
27. Vojnikovic B. Doxium® (calcium dobesilate) reduces blood hyperviscosity and lowers elevated intraocular pressure in patients with diabetic retinopathy and glaucoma. Ophthalmic Res 1991; 23: 12-20
28. Ribeiro L, Caillon P, Gamba G, et al. Efficacy of calcium dobesilate (Doxium®) on the blood-retinal barrier permeability in early diabetic retinopathy: a double-blind study. Presented at the ARVO 2004 meeting; 2004 Apr 25-29; Fort Lauderdale (FL)
29. Skovborg F, Nielsen AV, Schlichtkrull J, et al. Blood-viscosity in diabetic patients. Lancet 1966; I: 129-31
30. Pope Jr CH. Retinal capillary microaneurysms: a concept of pathogenesis. Diabetes 1960; 9: 9-13
31. Schroder S, Palinski W, Schmid-Schonbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 1991; 139: 81-100
32. Giusti C. Are phospholipid-binding antibodies implicated in the pathogenesis of diabetic microangiopathy? Med Hypotheses 2004; 63: 235-8
33. Vojnikovic B. Hyperviscosity in whole blood, plasma, and aqueous humor decreased by Doxium® (calcium dobesilate) in diabetics with retinopathy and glaucoma: a double-blind controlled study. Ophthalmic Res 1984; 16: 150-62
34. Salama-Benarroch I, Brodsky M, Rubinstein A, et al. Treatment of blood hyperviscosity with calcium dobesilate in patients with diabetic retinopathy. Ophthalmic Res 1985; 17: 131-8
35. Vinazzer H, Hachen HJ. Influence of calcium dobesilate (Doxium®) on blood viscosity and coagulation parameters in diabetic retinopathy. Vasa 1987; 16: 190-2
36. Barras JP, Michal M. Effect of calcium dobesilate on blood viscosity in diabetic microangiopathy: a review. Vasa 1986; 15: 200-5
37. Michal M, Gotti C. Effect of calcium dobesilate on platelet function. Thromb Res 1988; 51: 593-605
38. Benakis A, Glasson B, Bouvier CA, et al. Metabolism and pharmacokinetics of calcium dobesilate in humans. Therapie 1974; 29: 211-9
39. Allain H, Ramelet AA, Polard E, et al. Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids. Drug Saf 2004; 27: 649-60
40. Ciapponi S, Laffaire E, Roqué M. Calcium dobesilate for chronic venous insufficiency: a systematic review. Angiology 2004; 55: 147-54
41. Ibanez L, Ballarin E, Vidal X, et al. Agranulocytosis associated with calcium dobesilate clinical course and risk estimation with the case-control and the case-population approaches. Eur J Clin Pharmacol 2000; 56: 763-7
42. Ibanez L. Ballarin E, Vidal X, et al. Population-based drug-induced agranulocytosis. Arch Intern Med 2005; 165: 869-74
43. Zapater Hernandez P, Horga de la Parte JF, Garcia AG. Risk of drug-induced agranulocytosis: an approximation to risk analysis arising from spontaneous notification of agranulocytosis cases among patients treated with calcium dobesilate. An Med Interna 2002; 19: 275-82
44. Zapater P, Horga JF, Garcia A. Risk of drug-induced agranulocytosis: the case of calcium dobesilate. Eur J Clin Pharmacol 2003; 58: 767-72
45. Kowluru RA, Kennedy A. Therapeutic potential of anti-oxidants and diabetic retinopathy. Expert Opin Investig Drugs 2001; 10: 1665-76
46. Kowluru RA, Koppolu P. Diabetes-induced activation of caspase-3 in retina: effect of antioxidant therapy. Free Radic Res 2002; 36: 993-9
47. Kowluru RA, Tang J, Kern TS. Abnormalities of retinal metabolism in diabetes and experimental galactosemia: VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 2001; 50: 1938-42
48. Ansari NH, Zhang W, Fulep E, et al. Prevention of pericyte loss by trolox in diabetic rat retina. J Toxicol Environ Health A 1998; 54: 467-75
49. Hammes HP, Bartmann A, Engel L, et al. Antioxidant treatment of experimental diabetic retinopathy in rats with nicanartine. Diabetologia 1997; 40: 629-34
50. Bursell SE, Clermont AC, Aiello LP, et al. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 1999; 22: 1245-51
51. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASAB J 2002; 16: 438-40
52. Bergerhoff K, Clar C, Richter B. Aspirin in diabetic retinopathy: a systematic review. Endocrinol Metab Clin North Am 2002; 31: 779-93
53. Baudoin C, Bousser MG, Haguenau M, et al. Secondary prevention of strokes: role of platelet anti-aggregant drugs in diabetic and non-diabetic patients [letter]. Diabet Med 1985; 2: 145
54. ETDRS. Effects of aspirin treatment on diabetic retinopathy: ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Oph-thalmology 1991; 98: 757-65
55. Kohner EM. Aspirin for diabetic retinopathy. BMJ 2003; 327: 1060-1
56. Schonlau F, Rohdewald P. Pycnogenol for diabetic retinopathy: a review. Int Ophthalmol 2001; 24: 161-71
57. Setter SM, Campbell RK, Cahoon CJ. Biochemical pathways for microvascular complications of diabetes mellitus. Ann Pharmacother 2003; 37: 1858-66
58. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9
59. Gurler B, Vural H, Yilmaz N, et al. The role of oxidative stress in diabetic retinopathy. Eye 2000; 14: 730-5
60. King GL, Loeken MR. Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol 2004; 122: 333-8
61. Son SM, Whalin MK, Harrison DG, et al. Oxidative stress and diabetic vascular complications. Curr Diab Rep 2004; 4: 247-52
62. Stitt AW. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol 2003; 75: 95-108
63. Schmidt AM, Hori O, Cao R, et al. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 1996; 45 Suppl. 3: S77-80
64. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001; 27: 535-42
65. Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 283-90
66. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996; 114: 66-71
67. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-7
68. Endo M, Yanagisawa K, Tsuchida K, et al. Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy. Horm Metab Res 2001; 33: 317-22
69. Mamputu JC, Renier G. Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells: inhibitory effect of gliclazide. J Diabetes Complications 2002; 16: 284-93
70. Urata Y, Yamaguchi M, Higashiyama Y, et al. Reactive oxygen species accelerate production of vascular endothelial growth factor by advanced glycation end products in RAW264.7 mouse macrophages. Free Radic Biol Med 2002; 32: 688-701
71. Murata T, Nakagawa K, Khalil A, et al. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest 1996; 74: 819-25
72. Mathews MK, Merges C, McLeod DS, et al. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci 1997; 38: 2729-41
73. Uhlmann S, Friedrichs U, Eichler W, et al. Direct measurement of VEGF-induced nitric oxide production by choroidal endothelial cells. Microvasc Res 2001; 62: 179-89
74. Hoffmann S, Friedrichs U, Eichler W, et al. Advanced glycation end products induce choroidal endothelial cell proliferation, matrix metalloproteinase-2 and VEGF upregulation in vitro. Graefes Arch Clin Exp Ophthalmol 2002; 240: 996-1002
75. Ku DD, Zaleski JK, Liu S, et al. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 1993; 265: H586-92
76. Curtis TM, Scholfield CN. The role of lipids and protein kinase Cs in the pathogenesis of diabetic retinopathy. Diabetes Metab Res Rev 2004; 20: 28-43
77. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46: 1473-80
78. Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol 2002; 160: 501-9
79. Romeo G, Liu WH, Asnaghi V, et al. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 2002; 51: 2241-8
80. Hammes HP, Lin J, Renner O, et al. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 2002; 51: 3107-12
81. Ellis EA, Grant MB, Murray FT, et al. Increased NADH oxidase activity in the retina of the BBZ/Wor diabetic rat. Free Radic Biol Med 1998; 24: 111-20
82. Du Y, Smith MA, Miller CM, et al. Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine. J Neurochem 2002; 80: 771-9
83. Freedman BI, Wuerth JP, Cartwright K, et al. Design and baseline characteristics for the Aminoguanidine Clinical Trial In Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 1999; 20: 493-510
84. Vasan S, Foiles PG, Founds HW. Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links. Expert Opin Investig Drugs 2001; 10: 1977-87
85. The PKC-β Inhibitor Diabetic Retinopathy Study. 63rd Scientific Sessions of the American Diabetes Association; 2003 Jun 13-17; Louisiana
86. The PKC-β inhibitor diabetic macular edema. 18th annual International Diabetes Federation Meeting; 2003 Aug 24-29; Paris
87. Boehm BO, Lang GK, Jehle PM, et al. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 2001; 33: 300-6
88. Davis MI, Wilson SH, Grant MB. The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors. Horm Metab Res 2001; 33: 295-9
89. Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism 1996; 45: 67-71
90. Grant MB, Mames RN, Fitzgerald C, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 2000; 23: 504-9
91. Boehm BO, Lustig RH. Use of somatostatin receptor ligands in obesity and diabetic complications. Best Pract Res Clin Gastroenterol 2002; 16: 493-509
92. NHMRC (National Health and Medical Research Council). Clinical practice guidelines: management of diabetic retinopathy. Commonwealth of Australia. July 1997
93. van der Pijl JW, Lemkes HH, Frolich M, et al. Effect of danaparoid sodium on proteinuria, von Willebrand factor, and hard exudates in patients with diabetes mellitus type 2. J Am Soc Nephrol 1999; 10: 1331-6
94. van der Pijl JW, van der Woude FJ, Swart W, et al. Effect of danaparoid sodium on hard exudates in diabetic retinopathy. Lancet 1997; 350: 1743-5
95. Sjolie AK, Chaturvedi N. The retinal renin-angiotensin system: implications for therapy in diabetic retinopathy. J Hum Hypertens 2002; 16 Suppl. 3: S42-6
96. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes: the EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28-31
97. Lozovskaia EL, Kaplunskii GD, Sapezhinskii II. Superoxide dismutase activity and photosensitizing properties of 2,5-dihydroxybenzolsulfonate. Biophysics 1990; 35: 947-52
98. Brunet J, Garay R, Hannaert P. Calcium dobesilate has oxygen free radical scavenger properties [abstract]. Can J Physiol Pharmacol 1994; 72: 596
99. Brunet J, Farine JC, Garay RP, et al. In vitro antioxidant properties of calcium dobesilate. Fundam Clin Pharmacol 1998; 12: 205-12
100. Ruiz E, Lorente R, Tejerina T. Effects of calcium dobesilate on the synthesis of endothelium-dependent relaxing factors in rabbit isolated aorta. Br J Pharmacol 1997; 121: 711-6
101. Szabo ME, Haines D, Garay E, et al. Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina. Eur J Pharmacol 2001; 428: 277-86
102. Halliwell B, Gutteridge JMC, editors. Free radicals in biology and medicine. 3rd ed. Oxford: Oxford University Press, 1999
103. Brunet J, Farine JC, Garay RP, et al. Angioprotective action of calcium dobesilate against reactive oxygen species-induced capillary permeability in the rat. Eur J Pharmacol 1998; 358: 213-20
104. Bozkurt AK, Konukoglu D, Ustundag N, et al. Calcium dobesilate ameliorates lung injury following lower limb ischemia/reperfusion. Drugs Exp Clin Res 2002; 28: 127-32
105. Rota I, Chiavaroli C, Garay RP, et al. Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats. Eur J Pharmacol 2004; 495: 217-24
106. Ruiz E, Tejerina T. Calcium dobesilate increased endothelium-dependent relaxation in isolated rabbit aorta. Gen Pharmacol 1998; 30: 713-8
107. Sanz M, Ruiz E, Ganado P, et al. In vitro effects of calcium dobesilate on the responsiveness of spontaneously diabetic rat aorta. Jpn J Pharmacol 1998; 78: 391-4
108. Tejerina T, Ruiz E, Sanz M, et al. Study of calcium dobesilate in diabetic rats. Int J Angiol 1999; 8: 16-20
109. Ruiz E, Tejerina T. Calcium dobesilate increases endothelium-dependent relaxation in endothelium-injured rabbit aorta. Pharmacol Res 1998; 38: 361-6
110. Suschek C, Kolb H, Kolb-Bachofen V. Dobesilate enhances endothelial nitric oxide synthase-activity in macro- and microvascular endothelial cells. Br J Pharmacol 1997; 122: 1502-8
111. Schram MT, Stam F, de Jongh RT, et al. The effect of calcium dobesilate on vascular endothelial function, blood pressure, and markers of oxidation in obese male smokers: a placebo-controlled randomised clinical trial. Atherosclerosis 2003; 170: 59-72
112. Angulo J, Cuevas P, Fernández A, et al. Diabetes impairs endothelium-dependent relaxation of human penile vascular tissues mediated by NO and EDHF. Biochem Biophysical Res Commun 2003; 312: 1202-8
113. Pares-Herbuté N, Fliche E, Monnier L. Involvement of nitric oxide in the inhibition of aortic smooth muscle cell proliferation by calcium dobesilate. Int J Angiol 1999; 8: 5-10
114. Lameynardie S, Chiavaroli C, Travo P, et al. Inhibition of choroidal angiogenesis by calcium dobesilate in normal Wistar and diabetic GK rats. Eur J Pharmacol 2005; 510: 149-56
115. Losa GA, Graber R, Farine JC. Prevention of oxidation and apoptosis in human peripheral blood mononuclear cells exposed to calcium dobesilate. Int J Angiol 1999; 8: 11-5